Millennium Management
TCRX icon

Millennium Management’s TScan Therapeutics TCRX Stock Holding History

Millennium Management’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.47M Buy
1,460,285
+1,056,667
+262% +$1.13M ﹤0.01% 4120
2025
Q4 		$404K Sell
403,618
-62,468
-13% -$90.4K ﹤0.01% 5080
2025
Q3 		$848K Sell
466,086
-164,052
-26% -$291K ﹤0.01% 4740
2025
Q2 		$914K Buy
630,138
+398,963
+173% +$576K ﹤0.01% 4478
2025
Q1 		$319K Buy
+231,175
New +$500K ﹤0.01% 5070
2024
Q4 		– Sell
-48,672
Closed -$242K – 6451
2024
Q3 		$242K Buy
48,672
+20,783
+75% +$125K ﹤0.01% 5327
2024
Q2 		$163K Sell
27,889
-364,226
-93% -$2.87M ﹤0.01% 5212
2024
Q1 		$3.11M Buy
392,115
+293,033
+296% +$1.84M ﹤0.01% 3330
2023
Q4 		$578K Buy
+99,082
New +$454K ﹤0.01% 4554
2023
Q1 		– Sell
-19,244
Closed -$31K – 6846
2022
Q4 		$31K Buy
+19,244
New +$47.2K ﹤0.01% 5927
2022
Q1 		– Sell
-12,276
Closed -$55K – 7485
2021
Q4 		$55K Sell
12,276
-17,964
-59% -$130K ﹤0.01% 6452
2021
Q3 		$252K Buy
+30,240
New +$280K ﹤0.01% 5945

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Millennium Management's TCRX Position: Q1 2026 in Review

Millennium Management increased its TScan Therapeutics (TCRX) stake by 262% in Q1 2026, buying an estimated $1.13M and bringing the position to 1,460,285 shares worth $1.47M. The position accounts for ﹤0.01% of the portfolio, ranked #4120.

Millennium Management first reported a position in TCRX in Q3 2021 and has held it in 12 quarters since. The position peaked at $3.11M in Q1 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • Millennium Management held 1,460,285 shares of TScan Therapeutics worth $1.47M as of Q1 2026.
  • Millennium Management bought 1,056,667 TScan Therapeutics shares in Q1 2026, an estimated $1.13M.
  • TScan Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #4120 holding.
  • Millennium Management first reported a position in TScan Therapeutics in Q3 2021 and has held it in 12 quarters since.
  • Millennium Management's TScan Therapeutics position peaked at $3.11M in Q1 2024.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.